Literature DB >> 19421788

Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study.

Daniel I G Cubero1, Auro del Giglio.   

Abstract

OBJECTIVES: This study aims to evaluate the efficacy of methadone as substitute for morphine and to investigate if the addition of acetaminophen could reduce the time to attain an equianalgesic dose of methadone and/or to improve the level of pain control in oncologic patients. PATIENTS AND METHODS: Fifty patients on stable doses of morphine for 1 week were switched to methadone using a "stop-start" strategy and randomized in a double-blind fashion to receive either acetaminophen (750 mg PO every 6 hours) or placebo for a 7-day period. We collected data regarding level of pain, side effects, and quality of life.
RESULTS: Substitution of morphine for methadone resulted in a significant reduction in constipation (p < 0.001) and xerostomia (p = 0.03). There was also an improvement in the numeric pain scale (p = 0.03) as well as a significant improvement in the functional level and symptomatology according to the QLQ-C30 questionnaire. Addition of acetaminophen did not improve pain control or reduce the time of stabilization of analgesia once methadone was introduced. At the end of the study, most patients (70.8%, p = 0.001) preferred methadone to morphine.
CONCLUSIONS: Early switching from morphine to methadone was a safe and efficient strategy for the reduction of side effects and improvement of analgesia, allowing for a comfortable dosing regimen. In this scenario, the association with acetaminophen did not improve pain control or reduce the time to achieve an equianalgesic dose of methadone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19421788     DOI: 10.1007/s00520-009-0649-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

1.  Opioid rotation in the management of refractory cancer pain.

Authors:  Rose Anne Indelicato; Russell K Portenoy
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

2.  Statistical power calculations.

Authors:  R V Lenth
Journal:  J Anim Sci       Date:  2006-10-23       Impact factor: 3.159

3.  Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations.

Authors:  S Watanabe; M Belzile; N Kuehn; J Hanson; E Bruera
Journal:  Cancer Treat Rev       Date:  1996-01       Impact factor: 12.111

4.  Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators.

Authors:  Antonio Vigano'; David Fan; Eduardo Bruera
Journal:  Pain       Date:  1996-09       Impact factor: 6.961

5.  Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.

Authors:  Miguel Angel Benítez-Rosario; Manuel Feria; Antonio Salinas-Martín; Luis Pedro Martínez-Castillo; José Javier Martín-Ortega
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

6.  Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial.

Authors:  Martin Stockler; Janette Vardy; Avinesh Pillai; David Warr
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 7.  Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know.

Authors:  Mellar P Davis; Wael Lasheen; Pamela Gamier
Journal:  Oncology (Williston Park)       Date:  2007-09       Impact factor: 2.990

8.  Pain and its treatment in outpatients with metastatic cancer.

Authors:  C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

Review 9.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

10.  Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.

Authors:  S Mercadante; A Casuccio; A Agnello; R Serretta; L Calderone; L Barresi
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

View more
  6 in total

Review 1.  Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents.

Authors:  Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson; David G Williams; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

Review 2.  Oral paracetamol (acetaminophen) for cancer pain.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Ewan D McNicol; Rae F Bell; Daniel B Carr; Mairead McIntyre; Bee Wee
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

Review 3.  Pharmacological options for the management of refractory cancer pain-what is the evidence?

Authors:  B Afsharimani; K Kindl; P Good; J Hardy
Journal:  Support Care Cancer       Date:  2015-03-07       Impact factor: 3.603

Review 4.  Methadone for cancer pain.

Authors:  Alexander B Nicholson; Graeme R Watson; Sheena Derry; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2017-02-08

5.  Randomized double-blind controlled trial to assess the efficacy of intravenous acetaminophen associated with strong opioids in the treatment of acute pain in adult cancer patients: study protocol.

Authors:  Ofelia Leiva; Joel Castellano; Luz M Letelier; Luis Rojas; Paola Viviani; Antonio Gonzalez; Pedro Perez-Cruz
Journal:  Trials       Date:  2022-07-06       Impact factor: 2.728

6.  Systematic review and meta-analysis on non-opioid analgesics in palliative medicine.

Authors:  Robert H Schüchen; Martin Mücke; Milka Marinova; Dmitrij Kravchenko; Winfried Häuser; Lukas Radbruch; Rupert Conrad
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-29       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.